MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Quick Stats
Jun 15, 202664.2
AI Score
BUY0.08
Volume Ratio
Aug 05, 2026
Next Earnings
15
+ve Days (30d)
15
-ve Days (30d)
MNKD Stock Summary
Last updated
MNKD is currently trading at $3.755, positioned below its 200-day moving average of $4.55, suggesting bearish momentum. The stock has a 52-week range of $2.23 to $6.51.
Technical Analysis: The 50-day moving average stands at $3.12, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates MNKD at 64.2/100 with a BUY recommendation.
MNKD Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
MNKD Price vs Max Options Open Interest
MNKD Max Change In Options Open Interest
MNKD Options - Sort by Max open Interest (near term)
15th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
MNKD Daily Out of Money Options - Sort by Max open Interest (near term)
15th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
MNKD Daily In the Money Options - Sort by Max open Interest (near term)
15th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
MNKD Most Active Options by Volume(near term)
15th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Mannkind Corporation is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
MNKD Moving Averages Analysis
Mannkind Corporation has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jun 15, 2026
MNKD (Mannkind Corporation) Simple Moving Averages
Moving Averages are last updated Jun 15, 2026
| Days | MA |
|---|---|
| 10 | 3.55 |
| 20 | 3.47 |
| 30 | 3.39 |
| 50 | 3.12 |
| 100 | 3.6 |
| 200 | 4.55 |
MNKD Fundamental Analysis
| P/E (Forward) | 38.1679 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.2 billion |
| Earnings/Share ($) | -0.07 |
| Net Proft Margin (%) | -0.0663 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 0.085 |
| EPS Estimate Next Year ($) | 0.1925 |
| WallStreet Target Price ($) | 7.5938 |
| Most Recent Quarter |
MannKind Corporation's stock price dropped below $3 due to dilution news, but pediatric sales of Afrezza are expected to boost overall sales. Indycar/NASCAR driver Conor Daly, who uses inhalable insulin, will be racing again on July 24th. MannKind also received FDA approval for indication expansion in children and pregnant women. The company's stock has been on an uptrend and is expected to continue climbing.
Updated 2026-05-30 20:00:02